Therma Bright Investment Portfolio Company InStatin Secures Mountain West Research Discovery Study Agreement
Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment portfolio company InStatin on its recent agreement with Mountain West Research to conduct a comprehensive non-GLP discovery study. The pivotal study will explore the pharmacokinetics of the InStatin innovative statin...
2024-09-23 6:00 AM EDT
Therma Bright Announces Shares for Debt Issuance to Include Portfolio Company AI4LYF & IR Agreement
Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that AI4LYF has agreed to participate in a shares for debt transaction which progresses the Company's contractual obligation to AI4LYF while preserving cash. Therma Bright is the global exclusive license holder of the...
2024-09-18 6:00 AM EDT
Therma Bright Welcomes Medical Device & Pharmaceutical Veteran Douglas S. Sommerville to Its Advisory Board
Toronto, Ontario--(Newsfile Corp. - September 12, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the addition of Douglas S. Sommerville to its Advisory Board. With 30 years of experience in sales and operations within the medical device industry, Mr. Sommerville brings a wealth of expertise to the Company. Mr. Sommerville previously served as...
2024-09-12 6:00 AM EDT
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment partner InStatin's John Patton, Ph.D on receiving the prestigious Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery (RDD). John Patton, Ph.D, a renowned biotechnology...
2024-09-04 6:00 AM EDT
Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success
Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is thrilled to announce a groundbreaking achievement by its investment portfolio company, Inretio. Inretio's Preva® ischemic stroke clot removal device has successfully completed its third (3rd) human trial, as announced
2024-08-27 6:00 AM EDT
RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Toronto, Ontario--(Newsfile Corp. - August 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is proud to announce the addition of a new Nationwide U.S. Durable Medical Equipment (DME) distribution partner that has launched an initial Venowave sales program to gauge Medicare/Medicaid reim
2024-08-23 9:18 AM EDT
Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Toronto, Ontario--(Newsfile Corp. - August 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is proud to announce the addition of a new Nationwide U.S. Durable Medical Equipment (DME) distribution partner that has launched an initial Venowave sales program to gauge Medicare/Medicaid reim
2024-08-22 6:00 AM EDT
Venowave VW5 von Therma Bright sichert sich den permanenten HCPCS Code E0683 der Centers for Medicare & Medicaid Services des U.S.-amerikanischen Gesundheitsministeriums
Toronto, Ontario--(Newsfile Corp. - Dienstag, 20. August 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" oder das "Unternehmen"), ein Entwickler und Investitionspartner für eine breite Palette führender, proprietärer Diagnostik- und Medizingerätetechnologien, freut sich bekannt zu geben, dass sein Venowave VW5 am 16. August 2024 von den Centers for Medicare and Medicaid Services (CMS) des U.S.-amerikanischen Gesundheitsministeriums einen permanenten Code unter dem...
2024-08-20 3:33 PM EDT
Therma Bright's Venowave VW5 Secures Permanent HCPCS Code E0683 from U.S. DHHS's Centers for Medicare & Medicaid Services
Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it's Venowave VW5 has received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS)...
2024-08-19 9:20 AM EDT
Therma Bright's AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial
Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it's AI-powered Digital Cough Technology (DCT), with development partner AI4LYF, is currently being considered as a partner technology for a new innovative, disruptive chronic cough drug US-based clinical trial....
2024-08-16 6:00 AM EDT
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in sales and operations within the medical and pharmaceutical industries to its advisory board. With more than three (3) decades of experience, Mr. Raimondo...
2024-08-13 6:00 AM EDT
Therma Bright Expands InStatin Investment
Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its InStatin investment. With the recent capital raise, the Company has advanced funds to expand its investment in InStatin, as part of SAFE investment plan ("SAFE investment") initiated by InStatin. InStatin...
2024-08-06 6:22 AM EDT
Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a quick update from a recent notification from US Department of Health and Huma Services' (DHHS) Centers of Medicare and Medicaid (CMS). CMS has informed the Company of the pending permanent Current Procedural Terminology...
2024-08-01 7:13 AM EDT
Therma Bright's Venowave VW5 Secures FDA 510K Approval
Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has received the U.S. Food and Drug Administration's (FDA) approval on its 510K application request to correct the Venowave VW5 device's intended use, labeling, and description. This approval addresses...
2024-07-29 7:55 AM EDT
Therma Bright Engages Independent Trading Group as Market Maker
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ("ITG") to provide market-making services in accordance with TSX Venture Exchange TSXV policies, ITG will trade shares of the...
2024-07-18 10:11 AM EDT
Therma Bright Q2, 2024 Market Update On Business
Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a market update on the state of the business, including: $1,000,000 CAD private placement capital raise, Venowave's pending HCPCS and CPT® codes update, Digital Cough Analyzer, powered by AI4LYF, update, InStatin and...
2024-07-03 6:30 AM EDT
Therma Bright Closes Second & Final Tranche of Fully Subscribed Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the second and final tranche ("Final Tranche") of its previously announced $1,000,0000 non-brokered private placement (the "Offering"). Under the Final Tranche, Therma issued 14,550,000 units priced...
2024-06-21 6:00 AM EDT
Therma Bright Completes Debt Settlements
Toronto, Ontario--(Newsfile Corp. - June 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that further to its press release of May 22, 2024, it has now issued an aggregate of 19,250,000 common shares at a deemed price of $0.01 per share to settle aggregate debt of $192,500. All shares issued in relation to these debt...
2024-06-19 7:43 AM EDT
Therma Bright Closes $854,500 First Tranche of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the first tranche ("First Tranche") of its previously announced non-brokered private placement (the "Offering"). Under the First Tranche, Therma issued 85,450,000 units priced at $0.01 per unit for...
2024-06-10 8:02 AM EDT
Therma Bright Announces up to $1,000,000 Unit Offering
Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 100,000,000 units priced at $0.01 per unit for total proceeds of $1,000,000 (the "Offering"). Each unit will be comprised of one common share in the capital of the Company and...
2024-05-22 7:55 AM EDT